Skip to content
OpenCapital
Get started

Candel Therapeutics, Inc. CADL Q1 2025 earnings

Reported May 13, 2025 · Before market open

EPS$0.13Beat by $0.37
EPS estimate-$0.24

Next report

Aug 13, 2026 (In 2 weeks)
EPS estimate-$0.22

Financials

Q1 2025

Income statement

See full
Operating income-$8.1M-2.9%
Net income$7.4M+190%
EPS (diluted)$0.13+146%

Balance sheet

See full
Cash & equivalents$92.2M+258%
Total debt$10.9M-8.4%
Total equity$74.7M+1,149%
Total assets$95.9M+207%

Cash flow

See full
Operating cash flow-$8.6M-2.1%
CapEx$3.0K-57.1%
Free cash flow-$8.6M-2.1%

Valuation & ratios

Valuation

as of 03/31/25
See full
Market cap$266.88M+483%
Enterprise value$185.63M+480%

Returns & leverage

See full
Return on equity-98.1%-28.1pp
Debt / equity0.1×-1.8×
Current ratio4.6×+2.6×

Versus estimates

Diluted EPS

Q1 2026-$0.14Beat by $0.08Q4 2025-$0.54Miss by $0.30Q3 2025-$0.21Miss by $0.04Q2 2025-$0.09Beat by $0.08
Q1 2025$0.13Beat by $0.37
Q4 2024-$0.40Miss by $0.17

Ask the moment Candel Therapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Candel Therapeutics, Inc. report Q1 2025 earnings?
Candel Therapeutics, Inc. (CADL) reported Q1 2025 earnings on May 13, 2025 before market open.
What were Candel Therapeutics, Inc.'s Q1 2025 revenue and EPS?
Candel Therapeutics, Inc. reported eps of $0.13 for Q1 2025.
Did Candel Therapeutics, Inc. beat estimates in Q1 2025?
EPS beat the consensus estimate of $-0.24 by $0.37.
Where can I find Candel Therapeutics, Inc.'s Q1 2025 SEC filings?
You can read the 10-Q periodic report (0000950170-25-069833) directly on SEC EDGAR. The filing index links above go to sec.gov.